Diego A. Díaz-García: Biomarkers and Resistance Insights Transform NSCLC Care
Diego A. Díaz-García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology and Medical Oncologist at Angeles del Carmen Hospital, shared a post on X about a paper by Maxime Borgeaud et al. published in CA: A Cancer Journal for Clinicians:
“EGFR mutations reshaped NSCLC care. TKIs now impact early, locally advanced, and metastatic disease.
Biomarkers and resistance insights guide precision strategies for better outcomes.”
Title: Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management
Authors: Maxime Borgeaud, Timothée Olivier, Jair Bar, Stephanie Pei Li Saw, Kaushal Parikh, Giuseppe Luigi Banna, Claudio De Vito, Jill Feldman, Xiuning Le, Alfredo Addeo
You can read the Full Article on CA: A Cancer Journal for Clinicians.
More posts featuring Diego A. Díaz-García.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023